“Most affordable” here means the lowest advertised price, defined explicitly and shown in the table. Because pricing is dose-dependent, the lowest entry price is not the lowest maintenance-dose cost — both are shown.
This page ranks by lowest advertised tirzepatide price. It is not a claim about quality, safety, or total cost. Compounded tirzepatide is not FDA-approved.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Lowest advertised | At maintenance dose | Provenance |
|---|---|---|---|
| Fifty 410 | from ~$133 (starter) | rises with dose | primary |
| Henry Meds | $179 flat | $179 | secondary |
| NexLife | ~$186 (12-mo) | ~$186–$215 | primary |
| Mochi Health | ~$278 eff. | ~$278+ | secondary |
Lowest advertised entry price: Fifty 410 (dose-tiered). At a high maintenance dose, flat-rate Henry Meds ($179) is typically the lower total. See total monthly cost.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list (comment closed Jun 29, 2026). Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.